CN104800176A - Brivaracetam orally-disintegrating tablets and preparation method thereof - Google Patents
Brivaracetam orally-disintegrating tablets and preparation method thereof Download PDFInfo
- Publication number
- CN104800176A CN104800176A CN201510202995.4A CN201510202995A CN104800176A CN 104800176 A CN104800176 A CN 104800176A CN 201510202995 A CN201510202995 A CN 201510202995A CN 104800176 A CN104800176 A CN 104800176A
- Authority
- CN
- China
- Prior art keywords
- parts
- waxitan
- oral cavity
- disintegration tablet
- cavity disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 229960002161 brivaracetam Drugs 0.000 title abstract description 7
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 title abstract description 7
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract 5
- 239000000945 filler Substances 0.000 claims abstract description 12
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 210000000214 mouth Anatomy 0.000 claims description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 239000000741 silica gel Substances 0.000 claims description 15
- 229910002027 silica gel Inorganic materials 0.000 claims description 15
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 239000004376 Sucralose Substances 0.000 claims description 14
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 14
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 14
- 229940041616 menthol Drugs 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 14
- 235000019408 sucralose Nutrition 0.000 claims description 14
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 229940109275 cyclamate Drugs 0.000 claims description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229920003020 cross-linked polyethylene Polymers 0.000 claims description 2
- 239000004703 cross-linked polyethylene Substances 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- -1 iron alkane ketone Chemical class 0.000 claims description 2
- 238000009702 powder compression Methods 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229960001367 tartaric acid Drugs 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000019659 mouth feeling Nutrition 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 15
- 239000007788 liquid Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000003507 refrigerant Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004821 distillation Methods 0.000 description 5
- 239000004576 sand Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 230000003556 anti-epileptic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960002790 phenytoin sodium Drugs 0.000 description 2
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101000584505 Homo sapiens Synaptic vesicle glycoprotein 2A Proteins 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229950011546 carabersat Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- RCLXAPJEFHPYEG-ZWKOTPCHSA-N n-[(3r,4s)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide Chemical compound N([C@@H]1[C@@H](O)C(C)(C)OC2=CC=C(C=C21)C(=O)C)C(=O)C1=CC=C(F)C=C1 RCLXAPJEFHPYEG-ZWKOTPCHSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960003312 retigabine Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to brivaracetam orally-disintegrating tablets. The brivaracetam orally-disintegrating tablets can be prepared from the following components in parts by weight: 18-32 parts of brivaracetam, 2-10 parts of a disintegrating agent with rapid disintegration property, 30-75 parts of a hydrophilic filling agent, 1.45-4 parts of a flavoring agent and at least one of 0.2-1.5 parts of a lubricating agent and 0.5-2.5 parts of a flow aid. The invention also provides a preparation method of the brivaracetam orally-disintegrating tablets. The brivaracetam orally-disintegrating tablets provided by the invention have good disintegration property and mouth feeling, and the preparation method is simple and easy to operate.
Description
Technical field
The present invention relates to a kind of Bu Waxitan preparation, be specifically related to a kind of Bu Waxitan oral cavity disintegration tablet and preparation method thereof.
Background technology
Epilepsy is a kind of long-term chronic brain diseases, be the unexpected abnormal excessive of brain cell caused by cerebral lesion discharge cause brain function imbalance syndrome.At present, antiepileptic can be divided into three generations according to development history, and first on behalf of traditional classical AEDs, comprises phenytoin Sodium, carbamazepine and western natrium valericum etc.; Second on behalf of modern AEDs, comprises phenytoin Sodium, carbamazepine, levetiracetam and adds spray fourth etc.; The third generation is new A EDs, comprises Bu Waxitan, carabersat, retigabine etc.Bu Waxitan wherein, by the inhibitory action of SV2A height affinity interaction and sodium-ion channel, significantly improve antiepileptic activity, the good toleration aspect with good safety and pharmacokinetics, particularly central nervous system is obviously better than other antiepileptic.
Existing Bu Waxitan medicine, mainly comprising slow releasing tablet, is that the application for a patent for invention file of CN201410407641.9 discloses a kind of prolongation delivery formulations containing 2-OXo-1-pyrrolidine derivatives as the application number application for a patent for invention file that is CN200980120221.X discloses a kind of pharmaceutical composition, application number comprising Brivaracetam; Application number is that the application for a patent for invention file of CN200980145588.7 discloses a kind of prolongation delivery formulations comprising 2-OXo-1-pyrrolidine derivatives; Application number is that the application for a patent for invention file of CN200980145828.3 discloses a kind of prolongation delivery formulations containing 2-OXo-1-pyrrolidine derivatives; Application number is that the application for a patent for invention file of CN201410370727.9 discloses a kind of prolongation delivery formulations comprising 2-OXo-1-pyrrolidine derivatives.
But, the patient of epilepsy shows as unexpected unconsciousness and whole body convulsive seizure mostly, or show as unexpected disturbance of consciousness and muscular tension disappearance, or to show as head and muscle of upper extremity be that main bilateral rhythmicity myoclonus is twitched, or in status epilepticus (show as persistence outbreak or recurrent exerbation companion intermission consciousness function do not recover), therefore Bu Waxitan is prepared as the ordinary tablet or slow releasing tablet that need to swallow, the compliance that patient takes is very poor, even may block trachea, there is potential danger.
Summary of the invention
The object of the present invention is to provide and a kind ofly take safety, disintegrating property is good, mouthfeel is good a kind of Bu Waxitan oral cavity disintegration tablet, the present invention also provides the preparation method of this Bu Waxitan oral cavity disintegration tablet.
For solving the problem, the technical solution adopted in the present invention is as follows:
A kind of Bu Waxitan oral cavity disintegration tablet, it is prepared material and comprises following component according to parts by weight: Bu Waxitan 18-32 part, has disintegrating agent 2-10 part of fast disintegration property, hydrophilic filler 30-75 part, correctives 1.45-4 part, at least one in lubricant and fluidizer; Described lubricant is 0.2-1.5 part, and described fluidizer is 0.5-2.5 part.
In the present invention, preferred scheme is that the material of preparing of described Bu Waxitan oral cavity disintegration tablet also comprises non-hydrophilic filler 10-30 part.
In the present invention, preferred scheme is that described non-hydrophilic filler is selected from microcrystalline Cellulose, starch and cyclodextrin.
In the present invention, preferred scheme for described in there is fast disintegration property disintegrating agent be selected from crosslinked polyethylene pyrrole and iron alkane ketone, carboxymethyl starch sodium and cross-linking sodium carboxymethyl cellulose; Described correctives is one or more the combination in anhydrous citric acid, cyclamate, tartaric acid, menthol, sucralose, aspartame and essence.
In the present invention, preferred scheme is described fluidizer is micropowder silica gel and/or Pulvis Talci, and described lubricant is magnesium stearate and/or sodium stearyl fumarate, and described hydrophilic filler is at least one in mannitol, lactose, PEG-6000 and xylitol.
In the present invention, preferred scheme is that described Bu Waxitan oral cavity disintegration tablet is made up of the following component according to parts by weight: Bu Waxitan 18-32 part, microcrystalline Cellulose 10-30 part, mannitol 20-40 part, lactose 10-25 part, anhydrous citric acid 0.5-1 part, crospolyvinylpyrrolidone 2-10 part, sucralose 0.75-2 part, menthol 0.2-1, micropowder silica gel 0.5-2.5 part and sodium stearyl fumarate 0.2-1 part.Mannitol absorbs heat when disintegrate, makes user feel nice and cool, also has certain sweet feel simultaneously, and can not grittiness sense.
In the present invention, preferred scheme is that described Bu Waxitan oral cavity disintegration tablet is made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 21.6 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, crospolyvinylpyrrolidone 8 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.
The present invention also provides the preparation method of this Bu Waxitan oral cavity disintegration tablet, and it comprises the steps: to have taken each component, mix homogeneously according to formula ratio; Then direct powder compression method is utilized to obtain product.
The present invention also provides the preparation method of this Bu Waxitan oral cavity disintegration tablet, it comprises the steps: to have taken each component by formula, then by wet granulation after Bu Waxitan, the disintegrating agent with fast disintegration property, hydrophilic filler and correctives premix, dryly granule must be done, then add fluidizer, lubricant carries out tabletting, obtained product.
The present invention also provides the preparation method of this Bu Waxitan oral cavity disintegration tablet, and it comprises the steps: to have taken each component, mix homogeneously by formula, then adopts freeze-drying to obtain product.Freeze-drying, refer to medicine material to be added to the water and make medicinal liquid, then medicinal liquid is freezing at low temperatures, moisture contained in medicinal liquid is build-up ice, then dry under vacuum conditions, allow moisture be that gaseous state carries out dry method by solid state sublimation, the medicines structure obtained loosens, include a large amount of small spaces, the chance water capacity is soluble, is usually used in the preparation of disintegrating tablet.Freeze-drying, generally comprises pre-freeze (medicinal liquid made adding water freezes), distillation (sublimation drying), parsing-desiccation (redrying) three phases.In the present invention, adopt freeze-drying to prepare Bu Waxitan oral cavity disintegration tablet, its step is specific as follows: 1) medicinal liquid preparation: the medicine getting formula ratio is added to the water, and makes medicinal liquid; 2) pre-freeze: by medicinal liquid pre-freeze 2-20h at the temperature of-42 ~-38 DEG C; 3) distil: vacuum be 0.95-1.1mbar, baffle temperature be the condition of 4-6 DEG C under distillation process 14-18h; 4) parsing-desiccation: vacuum be 0.65-0.8mbar, baffle temperature be the condition of 23-27 DEG C under distillation process 2-4h, obtain product.
Compared with prior art, tool of the present invention has the following advantages: the Bu Waxitan of oral cavity disintegration tablet dosage form of the present invention, make patient directly medicine can be put into mouth when taking, medicine can run into saliva and disintegrate occurs, rear onset is absorbed along with the autonomous of patient or involuntary swallowing act enter digestive system, make to take medicine more light, safety, avoids the problems such as the administration when patient twitches of traditional medicine is difficult; In addition, formula of the present invention by the selection of component and proportioning thereof, such that the disintegrating property of Bu Waxitan oral cavity disintegration tablet is better, mouthfeel is better; In addition, its preparation method is simple, easy to operate.
Below in conjunction with detailed description of the invention, the present invention is described in detail.
Detailed description of the invention
Embodiment 1
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 21.6 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, crospolyvinylpyrrolidone 8 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.This Bu Waxitan oral cavity disintegration tablet is made up of following steps: taken each component by formula, mix homogeneously, then adopts freeze-drying to obtain product; Described freeze-drying step specific as follows: 1) medicinal liquid preparation: the medicine getting formula ratio is added to the water, and makes medicinal liquid; 2) pre-freeze: by medicinal liquid pre-freeze 12h at the temperature of-40 DEG C; 3) distil: vacuum be 1.05mbar, baffle temperature be the condition of 5 DEG C under distillation process 12h; 4) parsing-desiccation: vacuum be 0.75mbar, baffle temperature be the condition of 25 DEG C under distillation process 3h, obtain product.
Embodiment 2
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 18 parts, microcrystalline Cellulose 26 parts, 20 parts, mannitol, lactose 25 parts, anhydrous citric acid 0.5 part, crospolyvinylpyrrolidone 10 parts, sucralose 0.75 part, menthol 1, micropowder silica gel 0.5 part and sodium stearyl fumarate 1.5 parts.Its preparation method is with embodiment 1.
Embodiment 3
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 32 parts, microcrystalline Cellulose 26 parts, 40 parts, mannitol, lactose 10 parts, anhydrous citric acid 1 part, crospolyvinylpyrrolidone 2 parts, sucralose 2 parts, menthol 0.2, micropowder silica gel 2.5 parts and sodium stearyl fumarate 0.2 part.Its preparation method is with embodiment 1.
Embodiment 4
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of following steps: taken each component by formula, mix homogeneously, and then adopt freeze-drying to obtain product, its component, proportioning are all identical with embodiment 1.
Embodiment 5
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of following steps: taken each component by formula, mix homogeneously, then by wet granulation after Bu Waxitan, the disintegrating agent with fast disintegration property, hydrophilic filler and correctives premix, dryly granule must be done, then tabletting after additional lubricant, fluidizer, obtains product, and its component, proportioning are all identical with embodiment 1.
Comparative example 1
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 13.5 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, cross-linking sodium carboxymethyl cellulose 8 parts, cyclamate 1.5 parts, apple essence 0.5, micropowder silica gel 1.3 parts and magnesium stearate 0.4 part.Its preparation method is with embodiment 1.
Comparative example 2
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 23 parts, hydroxy methocel 13.5 parts, xylitol 32 parts, lactose 19 parts, 0.8 part, tartaric acid, crospolyvinylpyrrolidone 8 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.Its preparation method is with embodiment 1.
Comparative example 3
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 10 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, crospolyvinylpyrrolidone 8 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.Its preparation method is with embodiment 1.
Comparative example 4
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 28 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, crospolyvinylpyrrolidone 8 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.Its preparation method is with embodiment 1.
Comparative example 5
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 14 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, crospolyvinylpyrrolidone 10 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.Its preparation method is with embodiment 1.
Comparative example 6
A kind of Bu Waxitan oral cavity disintegration tablet, it is made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 14 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, crospolyvinylpyrrolidone 1.5 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.Its preparation method is with embodiment 1.
Experimental example
Choose hardness and be the obtained Bu Waxitan oral cavity disintegration tablet of embodiments of the invention 1-5, the comparative example 1-6 of 32 ± 5N, then its mouthfeel, disintegrating property are tested, wherein disintegrating property is mainly evaluated using disintegration as index, wherein for mouthfeel evaluation mainly with whether grittiness sense, whether have uncomfortable taste, whether there is refrigerant sense for index and evaluate.
Wherein:
Sand type appraisement system: 4 points, completely without sand type; 3 points, slightly sand type; 2 points, obviously feel grittiness sense; 1 point, serious sand type.
Taste evaluation system: 4 points, without uncomfortable taste; 3 points, slightly uncomfortable taste; 2 points, obviously to feel to have be not taste; 1 point, uncomfortable sense of taste is serious.
Refrigerant sense appraisement system: 4 points, very refrigerant; 3 points, refrigerant; 2 points, slightly refrigerant sense; 1 point, without refrigerant sense.
Choose 220 volunteers to test, 220 volunteers are divided into groups, often organize 20, often group corresponding by embodiment 1-5, the Bu Waxitan oral cavity disintegration tablet that comparative example 1-6 obtains puts into the mouth of volunteer, then record the time of the complete disintegrate of oral cavity disintegration tablet, after disintegrate completely, utilize clear water to gargle, then record volunteer Bu Waxitan oral cavity disintegration tablet mouthfeel is experienced, and mark, the score value calculating mean value then will often organized, concrete data refer to following table 1:
Table 1: embodiment 1-5, the Bu Waxitan oral cavity disintegration tablet disintegrating property of comparative example 1-6, mouthfeel evaluation table
| Disintegration/s | Sand type/point | Taste/point | Refrigerant sense/point | |
| Embodiment 1 | 12.8 | 4 | 4 | 3.9 |
| Embodiment 2 | 16.7 | 3.6 | 3.7 | 3.7 |
| Embodiment 3 | 17.2 | 3.7 | 3.5 | 3.6 |
| Embodiment 4 | 14.3 | 3.7 | 3.6 | 3.8 |
| Embodiment 5 | 13.9 | 3.8 | 3.7 | 3.8 |
| Comparative example 1 | 19.2 | 3.2 | 3.0 | 3.3 |
| Comparative example 2 | 20.1 | 3.1 | 2.9 | 3.1 |
| Comparative example 3 | 16.9 | 3.1 | 3.2 | 3.0 |
| Comparative example 4 | 18.2 | 3.4 | 3.2 | 3.2 |
| Comparative example 5 | 18.5 | 3.1 | 3.2 | 3.0 |
| Comparative example 6 | 23.1 | 3.0 | 3.1 | 3.3 |
From data in table 1, Bu Waxitan oral cavity disintegration tablet of the present invention has good disintegrating property and mouthfeel, and wherein embodiment 1 effect is optimum.
Above-mentioned embodiment is only the preferred embodiment of the present invention; can not limit the scope of protection of the invention with this, change and the replacement of any unsubstantiality that those skilled in the art does on basis of the present invention all belong to the present invention's scope required for protection.
Claims (10)
1. Yi Zhong Bu Waxitan oral cavity disintegration tablet, it is characterized in that it is prepared material and comprises following component according to parts by weight: Bu Waxitan 18-32 part, has disintegrating agent 2-10 part of fast disintegration property, hydrophilic filler 30-75 part, correctives 1.45-4 part, at least one in lubricant and fluidizer; Described lubricant is 0.2-1.5 part, and described fluidizer is 0.5-2.5 part.
2. Bu Waxitan oral cavity disintegration tablet according to claim 1, is characterized in that: the material of preparing of described Bu Waxitan oral cavity disintegration tablet also comprises non-hydrophilic filler 10-30 part.
3. Bu Waxitan oral cavity disintegration tablet according to claim 2, is characterized in that: described non-hydrophilic filler is selected from microcrystalline Cellulose, starch and cyclodextrin.
4. Bu Waxitan oral cavity disintegration tablet according to claim 1, is characterized in that: described in there is fast disintegration property disintegrating agent be selected from crosslinked polyethylene pyrrole and iron alkane ketone, carboxymethyl starch sodium and cross-linking sodium carboxymethyl cellulose; Described correctives is one or more the combination in anhydrous citric acid, cyclamate, tartaric acid, menthol, sucralose, aspartame and essence.
5. Bu Waxitan oral cavity disintegration tablet according to claim 1, it is characterized in that: described fluidizer is micropowder silica gel and/or Pulvis Talci, described lubricant is magnesium stearate and/or sodium stearyl fumarate, and described hydrophilic filler is at least one in mannitol, lactose, PEG-6000 and xylitol.
6. Bu Waxitan oral cavity disintegration tablet according to claim 1, is characterized in that being made up of the following component according to parts by weight: Bu Waxitan 18-32 part, microcrystalline Cellulose 10-30 part, mannitol 20-40 part, lactose 10-25 part, anhydrous citric acid 0.5-1 part, crospolyvinylpyrrolidone 2-10 part, sucralose 0.75-2 part, menthol 0.2-1, micropowder silica gel 0.5-2.5 part and sodium stearyl fumarate 0.2-1 part.
7. Bu Waxitan oral cavity disintegration tablet according to claim 6, is characterized in that being made up of the following component according to parts by weight: Bu Waxitan 23 parts, microcrystalline Cellulose 21.6 parts, 32 parts, mannitol, lactose 19 parts, anhydrous citric acid 0.8 part, crospolyvinylpyrrolidone 8 parts, sucralose 1.5 parts, menthol 0.5, micropowder silica gel 1.3 parts and sodium stearyl fumarate 0.4 part.
8. the preparation method of the Bu Waxitan oral cavity disintegration tablet according to any one of claim 1-7, is characterized in that comprising the steps: to have taken each component, mix homogeneously according to formula ratio; Then direct powder compression method is utilized to obtain product.
9. the preparation method of the Bu Waxitan oral cavity disintegration tablet according to any one of claim 1-7, it is characterized in that comprising the steps: to have taken each component by formula, then by wet granulation after Bu Waxitan, the disintegrating agent with fast disintegration property, hydrophilic filler and correctives premix, dryly granule must be done, then add fluidizer, lubricant carries out tabletting, obtained product.
10. the preparation method of the Bu Waxitan oral cavity disintegration tablet according to any one of claim 1-7, is characterized in that comprising the steps: to have taken each component, mix homogeneously by formula, then adopts freeze-drying to obtain product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510202995.4A CN104800176A (en) | 2015-04-23 | 2015-04-23 | Brivaracetam orally-disintegrating tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510202995.4A CN104800176A (en) | 2015-04-23 | 2015-04-23 | Brivaracetam orally-disintegrating tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104800176A true CN104800176A (en) | 2015-07-29 |
Family
ID=53685676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510202995.4A Pending CN104800176A (en) | 2015-04-23 | 2015-04-23 | Brivaracetam orally-disintegrating tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104800176A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190125725A1 (en) * | 2016-05-12 | 2019-05-02 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| CN109833300A (en) * | 2017-11-28 | 2019-06-04 | 浙江京新药业股份有限公司 | A kind of antiepileptic Orally administered composition and preparation method thereof |
| CN110638743A (en) * | 2019-10-25 | 2020-01-03 | 乐普制药科技有限公司 | Composition containing brivaracetam |
| CN111374956A (en) * | 2018-12-28 | 2020-07-07 | 上海迪赛诺生物医药有限公司 | Improved quick-release preparation of brivaracetam |
| CN113288872A (en) * | 2020-02-21 | 2021-08-24 | 广东东阳光药业有限公司 | Composition of 2-pyrrolidone derivative and preparation method thereof |
| CN114272216A (en) * | 2021-10-11 | 2022-04-05 | 浙江歌文达生物医药科技有限公司 | Freeze-dried preparation of 2-oxo-1-pyrrolidine derivative and preparation thereof |
| EP3964201A4 (en) * | 2020-07-09 | 2022-12-28 | Shanghai Bocimed Pharmaceutical Co., Ltd. | OPHTHALMIC PHARMACEUTICAL COMPOSITION, PROCESS FOR MANUFACTURE THEREOF AND APPLICATION THEREOF |
| EP4559454A1 (en) * | 2023-11-22 | 2025-05-28 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally disintegrating tablet formulations of brivaracetam |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010089372A1 (en) * | 2009-02-09 | 2010-08-12 | Ucb Pharma, S.A. | Pharmaceutical compositions comprising brivaracetam |
| CN102292071A (en) * | 2009-01-29 | 2011-12-21 | Ucb医药有限公司 | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
| CN102300562A (en) * | 2009-01-29 | 2011-12-28 | Ucb医药有限公司 | Pharmaceutical composition containing 2-oxo-1-pyrrolidine derivative |
-
2015
- 2015-04-23 CN CN201510202995.4A patent/CN104800176A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102292071A (en) * | 2009-01-29 | 2011-12-21 | Ucb医药有限公司 | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
| CN102300562A (en) * | 2009-01-29 | 2011-12-28 | Ucb医药有限公司 | Pharmaceutical composition containing 2-oxo-1-pyrrolidine derivative |
| CN104083328A (en) * | 2009-01-29 | 2014-10-08 | Ucb医药有限公司 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives |
| WO2010089372A1 (en) * | 2009-02-09 | 2010-08-12 | Ucb Pharma, S.A. | Pharmaceutical compositions comprising brivaracetam |
Non-Patent Citations (2)
| Title |
|---|
| J.斯沃布里克等: "《制剂技术百科全书》", 31 January 2009 * |
| 高申等: "《现代药物新剂型新技术》", 31 January 2002 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190125725A1 (en) * | 2016-05-12 | 2019-05-02 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| CN109833300A (en) * | 2017-11-28 | 2019-06-04 | 浙江京新药业股份有限公司 | A kind of antiepileptic Orally administered composition and preparation method thereof |
| CN111374956A (en) * | 2018-12-28 | 2020-07-07 | 上海迪赛诺生物医药有限公司 | Improved quick-release preparation of brivaracetam |
| CN110638743A (en) * | 2019-10-25 | 2020-01-03 | 乐普制药科技有限公司 | Composition containing brivaracetam |
| CN110638743B (en) * | 2019-10-25 | 2023-03-28 | 乐普制药科技有限公司 | Composition containing brivaracetam |
| CN113288872A (en) * | 2020-02-21 | 2021-08-24 | 广东东阳光药业有限公司 | Composition of 2-pyrrolidone derivative and preparation method thereof |
| EP3964201A4 (en) * | 2020-07-09 | 2022-12-28 | Shanghai Bocimed Pharmaceutical Co., Ltd. | OPHTHALMIC PHARMACEUTICAL COMPOSITION, PROCESS FOR MANUFACTURE THEREOF AND APPLICATION THEREOF |
| CN114272216A (en) * | 2021-10-11 | 2022-04-05 | 浙江歌文达生物医药科技有限公司 | Freeze-dried preparation of 2-oxo-1-pyrrolidine derivative and preparation thereof |
| CN114272216B (en) * | 2021-10-11 | 2023-07-04 | 浙江歌文达生物医药科技有限公司 | Freeze-dried preparation of 2-oxo-1-pyrrolidine derivative and preparation thereof |
| EP4559454A1 (en) * | 2023-11-22 | 2025-05-28 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally disintegrating tablet formulations of brivaracetam |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104800176A (en) | Brivaracetam orally-disintegrating tablets and preparation method thereof | |
| EP2832350B1 (en) | Method for producing disintegrating particulate composition comprising acid-type carboxymethylcellulose, disintegrating particulate composition comprising acid-type carboxymethylcellulose, and orally disintegrating tablet including disintegrating particulate composition comprising acid-type carboxymethylcellulose | |
| PT1145711E (en) | Flash-melt oral dosage formulation | |
| KR20110018424A (en) | Intraoral rapid disintegration tablets and preparation method thereof | |
| KR20100121509A (en) | Orally disintegrating tablets | |
| JP5610865B2 (en) | Solid preparation | |
| JP7783953B2 (en) | Tablets containing levetiracetam | |
| WO2019151405A1 (en) | Tablets and method for producing same | |
| JP7036856B2 (en) | Orally disintegrating tablet | |
| CN100490810C (en) | Flashmelt oral dosage formulation | |
| JP2007269789A (en) | Orally disintegrating tablets | |
| WO2015199356A1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| KR102395687B1 (en) | Solid preparations containing tofogliflozin and process of producing the same | |
| CN103655497B (en) | A kind of Montelukast Sodium oral disnitegration tablet and preparation method thereof | |
| JP2012046446A (en) | Method for producing intraorally disintegrating tablet containing zolpidem tartrate | |
| CA2773003A1 (en) | Orally disintegrating pharmaceutical dosage form containing aripiprazole | |
| CN102440973B (en) | Diphenhydramine citrate orally disintegrating tablet and preparation method thereof | |
| CN101874790A (en) | Rasagiline or its medicinal salt orally disintegrating tablet and preparation method thereof | |
| JP6775155B2 (en) | tablet | |
| KR20110097956A (en) | Decay | |
| JP2008050264A (en) | Dry granulated substance | |
| CN100386071C (en) | A medicine for treating cough and asthma and chronic bronchitis | |
| JP2019006748A (en) | Tablet containing seihai-to extract powder | |
| EP3069723B1 (en) | Naringin and levocetirizine hydrochloride pharmaceutical composition and preparation thereof | |
| CN102670533A (en) | Stable aripiprazole orally-disintegrating tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150729 |